In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
News|Podcasts|April 15, 2026
ACT Brief: Protocol Interpretation as Startup Bottleneck, Plausible Mechanism Framework, and Real-Time Trial Tracking Systems
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine how protocol interpretation and source document preparation delay study startup, how the plausible mechanism framework accelerates individualized therapy timelines, and how real-time tracking technologies improve supply chain and sample integrity in decentralized trials.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
Research from Tufts CSDD and CRIO identified protocol interpretation and source document preparation as an understudied bottleneck in study startup that may hold significant efficiency opportunities. Sites struggle with inconsistent documentation, misaligned procedures and timelines, and contradictory eligibility criteria, yet this process has received minimal attention despite potentially unlocking major improvements in activation speed.- In part one of a new video
interview , Mwango Kashoki, MD, MPH, senior vice president and global head of regulatory strategy at Parexel, explained how the plausible mechanism framework reshapes development timelines for individualized therapies. First-in-human studies can now serve as pivotal trials, giving sponsors earlier clarity on evidence needed for approval and dramatically compressing traditional development cycles. - In a new
Q&A from Pharmaceutical Executive, Deepak Prakash, VP of healthcare at Identiv, discussed how RFID and Bluetooth-enabled tracking technologies create continuous visibility across fragmented trial workflows. Real-time monitoring of samples, supply chain conditions, and patient compliance reduces manual reconciliation, improves data integrity, and enables earlier intervention before problems compound across sites and logistics networks.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
Trending on Applied Clinical Trials Online
1
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
2
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
3
Beyond the Molecule: Why Radiopharmaceutical Trials Require a New Operating Model
4
Operation TrialBlazer Leveraging New and Anticipated US Policy Changes in Early Development
5